Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Jun 30, 2020
Mar 31, 2020
Dec 31, 2019
Sep 30, 2019
Total Revenue
429,485
--
454,443
461,097
Cost of Revenue
97,967
--
95,899
96,949
Gross Profit
331,518
--
358,544
364,148
Operating Expenses
Research Development
182,139
--
172,812
172,963
Selling General and Administrative
175,412
--
187,900
170,112
Non Recurring
--
--
--
--
Others
14,912
--
16,994
17,063
Total Operating Expenses
372,463
--
377,706
360,138
Operating Income or Loss
(40,945)
--
(19,162)
4,010
Income from Continuing Operations
Total Other Income/Expenses Net
2,429
--
11,100
3,409
Earnings Before Interest And Taxes
(34,225)
--
(3,360)
16,098
Interest Expense
8,048
--
6,421
6,276
Income Before Tax
(42,273)
--
(9,781)
9,822
Income Tax Expense
(13,090)
--
(24,805)
(45,214)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(29,183)
--
15,024
55,036
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
--
0
0
Net Income
(29,183)
--
15,024
55,036
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(29,183)
--
15,024
55,036

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information